000275790 001__ 275790
000275790 005__ 20240229162333.0
000275790 0247_ $$2doi$$a10.1016/S2352-3026(23)00030-3
000275790 0247_ $$2ISSN$$a2352-3026
000275790 0247_ $$2ISSN$$a2451-9960
000275790 0247_ $$2altmetric$$aaltmetric:147264787
000275790 0247_ $$2pmid$$apmid:37142345
000275790 037__ $$aDKFZ-2023-00878
000275790 041__ $$aEnglish
000275790 082__ $$a610
000275790 1001_ $$aNanni, Cristina$$b0
000275790 245__ $$aEuropean Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
000275790 260__ $$aLondon [u.a.]$$bElsevier$$c2023
000275790 3367_ $$2DRIVER$$aarticle
000275790 3367_ $$2DataCite$$aOutput Types/Journal article
000275790 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683276520_32280$$xReview Article
000275790 3367_ $$2BibTeX$$aARTICLE
000275790 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275790 3367_ $$00$$2EndNote$$aJournal Article
000275790 520__ $$aGiven the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list of 153 statements based on the literature review to be agreed or disagreed with, with an additional statement added after the first round. Third, the 154 statements were scored by a panel of 26 experts purposively sampled from authors of published research on haematological tumours on a 1 (strongly disagree) to 9 (strongly agree) Likert scale in a two-round electronic Delphi review. The RAND and University of California Los Angeles appropriateness method was used for analysis. Between one and 14 systematic reviews were identified on each topic. All were rated as low to moderate quality. After two rounds of voting, there was consensus on 139 (90%) of 154 of the statements. There was consensus on most statements concerning the use of PET in non-Hodgkin and Hodgkin lymphoma. In multiple myeloma, more studies are required to define the optimal sequence for treatment assessment. Furthermore, nuclear medicine physicians and haematologists are awaiting consistent literature to introduce volumetric parameters, artificial intelligence, machine learning, and radiomics into routine practice.
000275790 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000275790 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000275790 7001_ $$aKobe, Carsten$$b1
000275790 7001_ $$aBaeßler, Bettina$$b2
000275790 7001_ $$aBaues, Christian$$b3
000275790 7001_ $$aBoellaard, Ronald$$b4
000275790 7001_ $$aBorchmann, Peter$$b5
000275790 7001_ $$aBuck, Andreas$$b6
000275790 7001_ $$aBuvat, Irène$$b7
000275790 7001_ $$aChapuy, Björn$$b8
000275790 7001_ $$aCheson, Bruce D$$b9
000275790 7001_ $$aChrzan, Robert$$b10
000275790 7001_ $$aCottereau, Ann-Segolene$$b11
000275790 7001_ $$aDührsen, Ulrich$$b12
000275790 7001_ $$aEikenes, Live$$b13
000275790 7001_ $$aHutchings, Martin$$b14
000275790 7001_ $$aJurczak, Wojciech$$b15
000275790 7001_ $$aKraeber-Bodéré, Françoise$$b16
000275790 7001_ $$aLopci, Egesta$$b17
000275790 7001_ $$aLuminari, Stefano$$b18
000275790 7001_ $$aMacLennan, Steven$$b19
000275790 7001_ $$aMikhaeel, N George$$b20
000275790 7001_ $$aNijland, Marcel$$b21
000275790 7001_ $$aRodríguez-Otero, Paula$$b22
000275790 7001_ $$aTreglia, Giorgio$$b23
000275790 7001_ $$aWithofs, Nadia$$b24
000275790 7001_ $$aZamagni, Elena$$b25
000275790 7001_ $$aZinzani, Pier Luigi$$b26
000275790 7001_ $$aZijlstra, Josée M$$b27
000275790 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b28
000275790 7001_ $$aKunikowska, Jolanta$$b29
000275790 773__ $$0PERI:(DE-600)2802056-X$$a10.1016/S2352-3026(23)00030-3$$gVol. 10, no. 5, p. e367 - e381$$n5$$pe367 - e381$$tThe lancet <London> / Haematology$$v10$$x2352-3026$$y2023
000275790 909CO $$ooai:inrepo02.dkfz.de:275790$$pVDB
000275790 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000275790 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000275790 9141_ $$y2023
000275790 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000275790 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000275790 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET HAEMATOL : 2022$$d2023-08-26
000275790 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000275790 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000275790 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000275790 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000275790 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bLANCET HAEMATOL : 2022$$d2023-08-26
000275790 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK ED ES zentral$$x0
000275790 980__ $$ajournal
000275790 980__ $$aVDB
000275790 980__ $$aI:(DE-He78)ED01-20160331
000275790 980__ $$aUNRESTRICTED